- Simple, automated, nanoliter-scale assays requiring as little as 1 µL of sample
- Ready-to-use kits are fully qualified for reliable use in clinical research
- Accuracy and precision meets or exceeds ELISA performance
March 25, 2014, Uppsala, Sweden — Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, today announced that EMD Millipore, Life Science division of Merck KGaA of Darmstadt, Germany, has released five new immunoassay kits designed specifically for use on Gyrolab™ xP workstation. The new, fully qualified GyroMark™ HT kits from EMD Millipore will enable clinical researchers and drug developers to generate valuable research data much faster than typical ELISA kits.
Traditional ELISAs can consume significant time, sample and reagents. With the fully automated, walk-away system from Gyros, up to 480 data points can be generated in a run.
“We are very pleased to be able to partner with Gyros to fill a commercial...
The initial launch includes five assays for important metabolic and toxicity biomarkers, such as GLP-1, Insulin, Clusterin and KIM-1. EMD Millipore plans to release additional kits this year and is offering custom kits for companies who have specific needs or unique or novel antibodies.
Because the Gyrolab platform employs microfluidic technology with parallel processing, it offers many advantages over traditional assays in addition to reagent and time savings. GyroMark HT assays provide:
- accuracy over a four-log dynamic range (compared to two logs for ELISAs)
- elimination of cross-talk and plate position artifacts
- simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference
Gyros’ Global Marketing Director Maria Hjortsmark commented: “Gyrolab system revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale and using a fully automated system. We are delighted that EMD Millipore has now chosen to work with us to develop off-the-shelf kits, to further reduce time to results, freeing up analyst time and offering an easier route to robust, reproducible data.”